Expert Insights on NSCLC: Unmet Needs and Innovations from ASCO 2024

Jason Porter, MD, outlines the most significant unaddressed challenges in treating and managing non-small cell lung cancer as the field approaches the American Society of Clinical Oncology's 2024 annual meeting.

Now Viewing

EP: 1.Expert Insights on NSCLC: Unmet Needs and Innovations from ASCO 2024

EP: 2.ASCO 2024: Key Findings of the LAURA Trial on Osimertinib for EGFR-Mutated NSCLC

EP: 3.Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024

EP: 4.Insights from the TROPION-Lung05 Trial at ASCO 2024

EP: 5.Long-Term Follow-Up from CheckMate 9LA at ASCO 2024

EP: 6.ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions

Related Videos

Related Content

Advertisement

July 29th 2025

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

AJMC Contributor

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 29th 2025

Setting Care Goals Early Is Key in Pulmonary Fibrosis

AJMC Contributor

With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 28th 2025

Long COVID More Common Among Socially Vulnerable Individuals

Brooke McCormick

Social risk factors significantly increase the likelihood of developing long COVID, highlighting the urgent need for equitable health care and support systems.

July 28th 2025

Gefurulimab for gMG Meets Key End Points in PREVAIL Trial

Marco Meglio

The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.

Related Content

Advertisement

July 29th 2025

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

AJMC Contributor

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 29th 2025

Setting Care Goals Early Is Key in Pulmonary Fibrosis

AJMC Contributor

With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 28th 2025

Long COVID More Common Among Socially Vulnerable Individuals

Brooke McCormick

Social risk factors significantly increase the likelihood of developing long COVID, highlighting the urgent need for equitable health care and support systems.

July 28th 2025

Gefurulimab for gMG Meets Key End Points in PREVAIL Trial

Marco Meglio

The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.